N端脑利钠肽前体在舒张性心力衰竭中的应用研究

目的分析舒张性心力衰竭患者血浆N端脑利钠肽前体（NT-proBNP）水平变化的意义。方法将58例舒张性心力衰竭患者设为心力衰竭组,其中Ⅲ级组11例,Ⅳ级组47例,分别于就诊次日空腹和心功能改善至Ⅰ～Ⅱ级后采血,采用免疫荧光法测定血浆NT-proBNP。选取20例心功能正常的入院检查者为对照组。结果舒张性心力衰竭组NT-proBNP较对照组显著升高（P〈0.01）,且随心力衰竭程度加重而升高（P〈0.01）;舒张性心力衰竭组随着心功能的改善NT-proBNP水平明显下降,与治疗前比较差异有统计学意义（P〈0.01）。结论舒张性心力衰竭时NT-proBNP升高,且随心功能损害加剧而升高明显,治疗后明显降低,提示NT-proBNP是可反映舒张性心力衰竭病情变化的指标,可用于舒张性心力衰竭患者的诊断及疗效观测。     

用N端B型利钠肽前体诊断心力衰竭120例临床分析

目的探讨心力衰竭采用N端B型利钠肽前体(NT-proBNP)诊断价值。方法选取心力衰竭患者120例,设为观察组,均为我院2013年6月至12月收治,采用NT-proBNP诊断,并就结果与同期收集的100例对照组非心力衰竭的健康体检者相同检查指标结果进行比较。结果观察组选取病例NT-proBNP明显高于对照组,LVEF值明显低于对照组,差异均有统计学意义(P0.05)。结论慢性心力衰竭诊断中,NT-proBNP具重要价值,且对治疗后NT-proBNP下降速率进行评估,可为预后判定提供有力的参考依据。     

老年舒张性心力衰竭中血N端脑钠肽前体的诊断价值

舒张性心力衰竭(DHF)是一组具有心力衰竭症状和体征,射血分数正常或轻度受损而舒张功能异常的临床综合征,且往往发生于收缩性心力衰竭之前,是一种独立的疾病,约占心力衰竭总数的1/3〔1〕,较多见于老年人,往往女性多于男性。B型钠尿肽(BNP)和N末端BNP,前体(NT-proBNP)作为心力衰     

收缩性心力衰竭和舒张性心力衰竭患者血浆N末端B型利钠肽原的

目的 探讨收缩性心力衰竭(HF)和舒张性HF患者血浆N末端B型利钠肽原(NT-proBNP)的差异及与年龄的关系.方法 收入2010年1月至2011年10月在山西省晋城市人民医院心内科住院的202例心力衰竭患者,其中收缩性HF 104例,舒张性HF 98例,所有患者均具有HF的症状、体征并行超声心动图检查.202例患者初次入院后判断纽约心脏病协会(NYHA)心功能分级,行超声心动图检查,入院后初始测定血浆NT-proBNP,比较其在收缩性与舒张性HF中的差别,并比较不同心功能组、不同年龄组血浆NT-proBNP的差异,并设20例健康人作为对照组.结果 收缩性HF、舒张性HF组血浆NT-proBNP均较正常对照组明显升高(P＜0.01),收缩性HF组血浆NT-proBNP显著高于舒张性HF组(P＜0.05).在任何年龄组,随着NYHA心功能分级的增高,NT-proBNP浓度升高(P＜0.05).随着年龄增长,NT-proBNP浓度呈现上升趋势,但差异未达统计学意义(P＞0.05).结论 收缩性HF患者血浆NT-proBNP水平高于舒张性HF患者,HF患者血浆NT-proBNP与NYHA心功能分级密切相关.NT-proBNP浓度与年龄无显著相关性.     

N端脑钠肽前体与心力衰竭的研究进展

脑钠肽和N端脑钠肽前体是心脏分泌的肽类激素。心力衰竭时,心室壁压力升高增加其分泌量。最近的研究发现N端脑钠肽前体是心力衰竭的诊断、预后、危险分层和个体化治疗有用的指标。本文综述近年来N端脑钠肽前体在心力衰竭中的研究进展。     

血浆N末端-脑钠肽前体在舒张性心力衰竭中的意义

目的:探讨血浆N末端-脑钠肽前体(NT-pro BNP)在诊断舒张性心力衰竭和评估其病情上的应用价值。方法:选取我院收治的失代偿性舒张性心力衰竭的患者58例为病例组,同时选取同期在我院体检,排除心脏器质性病变的健康人群30例作为对照组。对比两组患者的血浆NT-pro BNP的检测结果;对比不同NYHA心功能分级的病例组患者的血浆NT-pro BNP检测结果;对比不同严重程度的左心室舒张功能障碍的病例组患者的血浆NT-pro BNP检测结果。结果:病例组患者血浆NT-pro BNP水平为(1 238.26±318.63)ng/L,两组差异有统计学意义(P0.05);NYHA心功能分级Ⅳ级患者的血浆NTpro BNP水平显著高于NYHA心功能分级Ⅲ级和Ⅱ级患者的血浆NT-pro BNP水平(均P0.05);NYHA心功能分级Ⅲ级患者的血浆NT-pro BNP水平显著高于NYHA心功能分级Ⅱ级患者的血浆NT-pro BNP水平(P0.05);重度左心室舒张功能障碍患者的血浆NT-pro BNP和二尖瓣环舒张早期运动速度/二尖瓣环舒张晚期运动速度水平显著高于中度和轻度左心室舒张功能障碍患者(均P0.05);中度左心室舒张功能障碍患者的血浆NT-pro BNP和二尖瓣环舒张早期运动速度/二尖瓣环舒张晚期运动速度水平显著高于轻度左心室舒张功能障碍患者(均P0.05)。结论:检测血浆NT-pro BNP有助于评估舒张性心力衰竭患者的心功能和左心室舒张功能的受损情况,对本病的临床诊治有一定的指导意义。     

慢性心力衰竭患者尿的N端-B型利钠肽前体

目前认为N端-B型利钠肽前体（NT—proBNP）主要通过尿排泄。尿NT—proBNP测量的临床意义尚不甚明了。 方法及结果观察94例慢性心力衰竭（CHF）病人（年龄58±11岁，男性79％）和20例年龄、性别相配的健康对照者，分别以^125I—iothalomate消除和^131I-hippuran反映肾小球滤过率和有效肾血浆流量，测24h尿及血浆NT—proBNP水平。CHF病人的平均左室射血分数为0．28±0．09。与对照者比较，CHF病人血浆NT-proBNP水平较高（中值为547pg／ml及41pg／ml，P〈0．001）。     

老年房颤患者血浆apelin水平及与N端B型利钠肽前体和左房内径的关系

目的探讨老年房颤患者血浆apelin的表达水平及其与N端B型利钠肽前体(NT-pro BNP)、左房内径(LAD)的关系。方法 122例老年房颤患者,其中53例为阵发性房颤(阵发组),36例为持续性房颤(持续组),33例为永久性房颤(永久组),并于同期随机选取40例非房颤患者为对照组,采用酶联免疫吸附法(ELISA)检测血浆apelin和NT-pro BNP水平,心脏多普勒超声诊断仪测定LAD、左心室射血分数(LVEF),并分析apelin与NT-pro BNP、LAD的关系。结果阵发组、持续组、永久组血浆apelin水平低于对照组,持续组、永久组血浆apelin水平低于阵发组,永久组血浆apelin水平低于持续组(P<0.05);阵发组、持续组、永久组NT-pro BNP、LAD高于对照组,持续组、永久组NT-pro BNP、LAD高于阵发组,永久组NTpro BNP、LAD高于持续组(P<0.05)。经Pearson积矩相关分析,老年房颤患者血浆apelin与NT-pro BNP、LAD均呈负相关关系(r=-0.675、-0.772,P<0.05)。结论老年房颤患者血浆apelin水平降低,并且apelin通过抗纤维化作用而参与心肌重构,进而参与房颤的发生及维持过程。     

氨基本段B型利钠肽前体检测对心力衰竭诊治的临床意义

<正>利钠肽家族主要由A型利钠肽(ANP)、B型利钠肽(BNP)、C型利钠肽(CNP)、肾利钠肽及树眼镜蛇属利钠肽等组成。其中,BNP和氨基末段BNP前体(NT-pro BNP)主要在心脏负荷增加时由心肌细胞分泌,是人体中一类重要的心脏生物标志物,对于多种心血管疾病,尤其是心力衰竭(HF)的诊治具有重要的临床意义。本文就NT-pro BNP的来源,与心功能的关系及其对HF诊断、治疗及预后的价值作一简要阐述。1 NT-pro BNP与BNP BNP是在1988年由日本学者Sudoh等〔1〕首次从猪大脑中     

慢性心力衰竭患者N端脑钠肽前体、内皮素与心功能的关系

目的探讨慢性心力衰竭(心衰,CHF)患者N端脑钠肽前体(NT-proBNP)、内皮素(ET)水平与心功能的关系。方法入选56例CHF患者作为研究对象,29例心功能正常者作为对照组。心衰患者按照NYHA分级分为心功能Ⅱ级、Ⅲ级、Ⅳ级3个亚组,分别测定患者NT-proBNP、ET水平,同时用心脏彩色多普勒超声心动仪测定左室射血分数(LVEF)和左室舒张末期内径(LVDD)并进行组间比较及相关性分析。结果对照组及CHF心功能Ⅱ级、Ⅲ级、Ⅳ级亚组的患者NT-proBNP水平分别为(336.24±41.25)ng/ml、(1761.35±21.43)ng/ml、(2693.45±41.54)ng/ml、(3161.26±67.56)ng/ml,ET水平分别为(19.89±11.35)ng/L、(48.60±21.25)ng/L、(61.56±31.68)ng/L、(161.67±46.56)ng/L。对照组患者及CHF心功能Ⅱ级组、Ⅲ级组、Ⅳ级组患者血浆NT-proBNP、ET水平呈逐渐增高趋势,差异具有显著统计学意义(P0.01)。除心功能Ⅱ级组与心功能Ⅲ级组间ET与LVEF水平比较无统计学差异(P0.051),其余各组间NT-proBNP、ET水平及LVEF、LVDD水平比较,均有显著统计学差异(P均0.01)。NT-proBNP与心功能分级呈正相关(r=0.769,P0.05),与LVDD呈正相关(r=0.606,P0.05),与LVEF呈负相关(r=-0.656,P0.05)。ET水平与心功能分级呈正相关(r=0.357,P0.05),与LVDD呈正相关(r=0.265,P0.05),与LVEF呈负相关(r=-0.274,P0.05)。结论 CHF患者NT-proBNP与ET水平随心力衰竭程度的加重而相应升高,与心功能分级有良好的相关性,对心力衰竭患者心力衰竭严重程度及预后的评价有意义。     

脑钠肽结合超声多普勒评价舒张性心力衰竭患者的心功能

目的 采用血浆脑钠肽(BNP)浓度测定结合超声多普勒心动图的参数来评价舒张性心力衰竭患者的心功能,为临床提供判断舒张性心力衰竭及其严重程度的敏感和特异的客观指标.方法 选择舒张性心力衰竭患者85例(心力衰竭组),按纽约心脏病学会(NYHA)心功能分级,Ⅱ级31例、Ⅲ级36例、Ⅳ级18例,以及健康对照组30例.测定血浆BNP浓度,超声多普勒结合组织多普勒显像(TDI)测定左室结构、左室舒张功能及左室舒张末压.结果 舒张性心力衰竭患者血浆BNP浓度明显高于对照组(P<0.001),且随心力衰竭程度加重而逐渐升高(P<0.001).舒张性心力衰竭组左房内径(LA)、室间隔厚度(IVS)、左室后壁厚度(LVPW)、舒张早期流速峰值/舒张早期速度峰值(E/Em)较对照组升高,E/舒张晚期流速峰值(A)降低(P<0.01),血浆BNP浓度与E/A比值呈负相关(r=-0.634,P<0.01),与E/Em比值呈正相关(r=0.728,P<0.01).结论 血浆BNP浓度测定结合超声多普勒心动图的参数判断舒张性心力衰竭患者的心功能简便准确.     

舒张功能不全心力衰竭研究的现状

约有50％充血性心力衰竭患者左室射血分数并未下降,这一亚群心力衰竭患者与左室射血分数下降心力衰竭患者存在许多明显的差异,目前已引起了相当的重视。现就其定义、诊断、流行病学调查情况、临床特点、治疗方法及预后等问题的现状作一简要的介绍。     

脑型利钠多肽研究进展

慢性心力衰竭的远期治疗效果差是临床面临的主要难题之一,近年来关于利钠多肽的研究是该领域进展的重要组成部分。根据现有的资料,对脑型利钠多肽在心血管疾病中的价值进行比较详细的回顾。     

血浆脑利钠肽及N末端脑钠肽原在心血管非心力衰竭领域中的应用

脑利钠肽是由心室肌细胞分泌的一种多肽类心脏激素,是利钠肽家族中的一员,它和相应的N端残基即N末端脑钠肽原一起,当心室壁张力升高时分泌量增加,它们广泛应用于心力衰竭的早期诊断、指导治疗以及判断患者预后.近年来,随着对血浆脑利钠肽及N末端脑钠肽原研究的不断深入,其在心血管非心力衰竭领域的应用也日益广泛,现就血浆脑利钠肽及N末端脑钠肽原的基本理论及其在心血管非心力衰竭领域的应用做一综述.     

检测血心钠肽水平对舒张性心力衰竭的诊断意义

目的:探讨测定血心钠肽(ANP)水平对诊断舒张性心力衰竭(DHF)的意义.方法:选择66例DHF患者作为实验组、64例非DHF的呼吸困难患者作为对照组,应用酶联免疫吸附测定法(ELISA)测定其血清ANP和脑钠素(BNP)水平,同时行心脏B超检查.并据ANP水平等对实验组和对照组进行分析判断.结果:DHF组的ANP水平...     

舒张功能不全性心力衰竭分子机制的研究进展

舒张功能不全性心力衰竭是一种以心力衰竭的症状和体征,正常的射血分数和异常的舒张功能为特征的病理生理综合征。在分子水平上,舒张功能受到心肌肌质网钙泵、钠钙交换体、细胞外基质以及它们的调节蛋白的活动等因素的影响。因此,任何影响上述代谢的因素都可能影响心肌的舒张,并最终发展为舒张功能不全性心力衰竭。现主要阐述近年来舒张功能不全性心力衰竭分子机制的研究进展。     

Novel Strategies for the Detection of Systolic and Diastolic Heart Failure

The incidence and prevalence of dyspnea increases with age. Frequently, for the general practitioner with his limited diagnostic facilities, it is impossible to separate dyspnea from cardiac causes and non-cardiac causes. Without cardiac imaging it is also impossible to separate systolic dysfunction from diastolic dysfunction. After a thorough physical examination, initial screening of systolic and diastolic heart failure can be done by measurement of plasma NT-pro BNP or plasma BNP. Additionally a Chest X-Ray or ECG can be performed. To improve diagnostic performance an open access echocardiographic service can be initiated. Recent studies showed, that open access echocardiography can easily detect systolic and diastolic dysfunction in the community and can separate cardiac from non-cardiac dyspnea.     

Diastolic Heart Failure in the Elderly

It is now clear that diastolic heart failure (DHF) is an important, perhaps even dominant form of heart failure in older Americans. However, our knowledge base regarding the epidemiology, pathophysiology, natural history, and therapy of this relatively recently recognized disorder is limited. A number of normal age related changes in the heart and vascular system may predispose to or lower the threshold for expression of DHF. Recent reports from large population-based observational studies indicate that over 50% of persons 65 years and older who have heart failure have normal LV systolic function (presumed DHF). Among these, 45% have no other confounding variables (coronary, valvular, or pulmonary disease) and meet the criteria for isolated DHF. DHF is substantially more common in older women than men. A history of systemic hypertension and left ventricular hypertrophy are almost invariably present. Mortality rates are about 50% lower in DHF than in systolic heart failure (SHF) when stable outpatients are considered. However, in hospitalized and very elderly patients, the mortality rate appears similar in DHF and SHF. Furthermore, due to its higher prevalence, the total mortality in the older population attributable to DHF exceeds that of SHF. Morbidity in DHF is substantial and approaches that of SHF.In the chronic setting, DHF patients can have severe exercise intolerance related to failure of the Frank-Starling mechanism with reduced peak cardiac output, heart rate, and stroke volume and increased LV filling pressure. DHF patients also appear to have increased vascular stiffness, accelerated systolic blood pressure response to exercise, neuroendocrine activation, and reduced quality of life. Acute exacerbations (pulmonary edema) frequently occur and are associated with severe hypertension, sodium indiscretion, and medication non-compliance. Surprisingly, overt myocardial ischemia appears to infrequently play a role in these acute exacerbations.Therapy is currently empiric and multicenter, randomized, controlled trials are urgently needed. Anecdotally, control of blood pressure appears to improve symptoms and reduce the frequency of acute exacerbations. In addition, non-pharmacologic intervention, including multi-disciplinary case management is useful.     

B-Type Natriuretic Peptide: Spectrum of Application. Nesiritide (Recombinant BNP) for Heart Failure

The therapeutic goals for patients hospitalized with acutely decompensated heart failure are to reverse acute hemodynamic abnormalities, relieve symptoms, and to initiate heart failure therapies which will decrease disease progression and improve long-term survival. Nesiritide (recombinant B-type natriuretic peptide) is the first in a new class of therapeutic agents for the treatment of heart failure and has been demonstrated to offer a unique combination of safety and efficacy. The use of nesiritide on top of standard care including diuretic therapy, has been proven to lead to meaningful clinical benefits in a broad range of acutely decompensated heart failure patients. Nesiritide is an attractive therapeutic option because of its more rapid and sustained hemodynamic profile, more favorable effects on neurohormonal suppression, with less adverse effects than alternative intravenous heart failure treatments such as nitroglycerine, nitroprusside, dobutamine, or milrinone. The use of nesiritide is the most effective initial treatment approach among currently available strategies to reverse acutely decompensated heart failure and to facilitate optimization of the heart failure medical regimen.     

Relationship between heart failure and the early NT-proBNP in burn patients

Background Myocardial damage often occurs after burns.Previously,cardiac enzyme profile was often measured to determine myocardial injury,but was hardly specific.In this study,we investigated early changes of plasma N-terminal pro-brain natriuretic peptide(NT-proBNP) over time and its diagnostic value in burned patients.Methods 39 patients with heat burned were assigned to heart failure group(n = 9),control group(n = 30).Plasma NT-ProBNP and troponin I(cTnT) were measured at 1st,3rd,5th days and 7th day,and patients were subdivided into 2 groups according to their cardiac function.Results Nine patients had heart failure(27.7%) and their NT-proBNP was 1676.03 ± 2190.41 pg /L.Significant difference was found between the heart failure group and control group(P < 0.01).Conclusion NT-proBNP is related to the severity of burning and can well reflect the status of myocardial injury in patients with severe burn,and can be used as an ideal marker for myocardial injury in burned patients.